Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. 1996

M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
Anxiety Disorders Program, Massachusetts General Hospital, Boston 02114, USA.

Venlafaxine has demonstrated efficacy for depression, and recent reports and clinical experience suggest that it may be effective for the treatment of anxiety disorders as well. We present what we believe are the first data from a controlled study designed to test the efficacy of venlafaxine for the treatment of panic disorder. There were 25 patients enrolled at one site of a five-center study; 13 received venlafaxine and 12 received placebo. There were more dropouts for placebo than for venlafaxine (8/12 vs. 2/13) in this 8-week acute trial. Patients treated with venlafaxine experienced significantly greater global improvement than those on placebo and exhibited trends toward greater improvement on anxiety and depression symptoms as assessed by the Hamilton rating scales. These data encourage further evaluation of venlafaxine for the treatment of panic disorder.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003511 Cyclohexanols Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers. Cyclohexanol
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069470 Venlafaxine Hydrochloride A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT. 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl,Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride,Dobupal,Efexor,Effexor,Sila-Venlafaxine,Trevilor,Vandral,Venlafaxine,Wy 45030,Wy-45,030,Wy-45030,Hydrochloride, Venlafaxine,Sila Venlafaxine,Wy 45,030,Wy45,030,Wy45030
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016584 Panic Disorder A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait. Panic Attacks,Attack, Panic,Attacks, Panic,Disorder, Panic,Disorders, Panic,Panic Attack,Panic Disorders
D018687 Antidepressive Agents, Second-Generation A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. Antidepressants, Atypical,Atypical Antidepressants,Second-Generation Antidepressive Agents,Antidepressive Drugs, Second-Generation,Agents, Second-Generation Antidepressive,Antidepressive Agents, Second Generation,Antidepressive Drugs, Second Generation,Drugs, Second-Generation Antidepressive,Second Generation Antidepressive Agents,Second-Generation Antidepressive Drugs

Related Publications

M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
October 2005, The British journal of psychiatry : the journal of mental science,
M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
July 1996, Journal of affective disorders,
M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
May 2005, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
April 2009, The Journal of clinical psychiatry,
M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
February 1991, The Journal of clinical psychiatry,
M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
July 1995, The American journal of psychiatry,
M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
September 1995, The British journal of psychiatry : the journal of mental science,
M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
January 1990, Psychopharmacology,
M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
January 1998, The American journal of psychiatry,
M H Pollack, and J J Worthington, and M W Otto, and K M Maki, and J W Smoller, and G G Manfro, and R Rudolph, and J F Rosenbaum
November 2003, The Journal of clinical psychiatry,
Copied contents to your clipboard!